InvestSMART

Cleo Diagnostics Ltd (ASX:COV)

ALERT: Price-sensitive ASX Announcement for COV
Current share price for COV : $0.360 -0.275 (-43.31%)+
Announcement
Release
20 May 2026 9:25AM
Price at Release
$0.635
Full Release
download
Summary
Cleo Diagnostics Ltd (ASX:COV) has outlined a strategic plan for entering the U.S. market with its Pre-Surgical Ovarian Cancer Test, leveraging the existing miscellaneous CPT code 81599 to facilitate immediate market entry and revenue generation post-FDA clearance. The reimbursement pathway is determined on a payer-by-payer basis, using comparable diagnostic tests as pricing references, with reimbursement levels for existing tests ranging from approximately US$500 to US$900. The company's strategy includes securing a dedicated CPT code for long-term reimbursement, supporting broader adoption, and standardizing utilization tracking. CLEO is also focusing on real-world evidence generation and strategic market access to underpin future CPT code applications.
Key Points
  • CLEO establishes U.S. reimbursement pathway using CPT code 81599.
  • Immediate market entry and revenue generation post-FDA clearance.
  • Reimbursement levels for comparable tests range from ~US$500–$900 per test.
  • The pathway allows early prescribing and clinical use in U.S. healthcare settings.
  • CLEO plans to apply for a dedicated CPT code to enhance reimbursement consistency.
  • The strategy includes generating real-world evidence to support future CPT applications.
  • CLEO's plan involves health economics and budget impact model development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.